Journal for ImmunoTherapy of Cancer-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1057918, encodeId=6cda105e9181e, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗;病原生物 经验分享：再被cns子刊一顿拒稿之后，终于在这接收了。从投稿到接收，一直都非常迅速，感人主编很给力。 4.22提交 5.4一审大修遇到两个发nature大佬，提了一大堆意见，其中1号一直很很肯定我们的研究 6.23修回 7.14二审大修 2号审稿人同意接收，可惜1号换人了，提了几个和文章无关很无理的问题 9.15修回 9.24三审小修几个单词错误，迅速修回去 9.27修回 10.1 接收 希望大家都好运，搞个科研不容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/07/ccdcbbe305c3370f7fc7637823aaeac0.jpg, createdBy=07fb2397125, createdName=浅沫, createdTime=Tue Oct 05 16:42:40 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099313, encodeId=d13520993130c, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：期刊效率非常高，对国人也比较友好 16-Aug-2022 Submitted 06-Sep-2022 Major Revision，大概1个月修回 24-Oct-2022 Minor Revision 03-Nov-2022 Accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epnJfSTyULHTUrbH2uCHYKgYccbS9AxlFkJ7ic0F0ZicWcM0LTv0LQibTtibeAeJRgWlLfdPBbicmPicPlw/132, createdBy=bd1f2020528, createdName=明日之星, createdTime=Wed Nov 09 08:12:06 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113407, encodeId=34b3211340e44, content=为什么这个杂志，一直是中科院二区？我有点想不通，小c d d，C a n c e r l e t t e r s这种都是一区了，是不是大水刊啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a452506975, createdName=124af5c7m81暂无昵称, createdTime=Tue Feb 07 11:15:57 CST 2023, time=2023-02-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1238075, encodeId=e32a12380e5ce, content=偏重的研究方向：肿瘤;生信 经验分享：请问这个杂志还收纯生信么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f79f6545001, createdName=ms8000001825855908, createdTime=Thu Aug 11 15:24:36 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231526, encodeId=d37d123152662, content=请问这个杂志接收case report么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211004/299253452aeb48dc9e0f8987e1a1cfe3/53348402bc724865bd8321a5f9b46bdb.jpg, createdBy=01db5551318, createdName=mkggdjkngfyikfddh, createdTime=Sat Jul 09 20:30:40 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107102, encodeId=c959110e102ff, content=文章题目需要注意些什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107101, encodeId=fbeb110e10100, content=文章题目应该包含哪些点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966060, encodeId=70539660602e, content=审稿速度:3.0 偏重的研究方向：肿瘤代谢;免疫 经验分享：中了一篇，审稿三月，修回后2个半月接收。感觉这个杂志目前的文章质量不错，基本都是老外的文章，期待杂志越办越好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0fa046123, createdName=mmz666, createdTime=Sun May 16 17:13:30 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588565, encodeId=6621588565d9, content=好的，谢谢vapor93 2020-04-09 00:00:00 发表: 没有，显示的是awaiting reviewer scroes., beContent=vapor93 2020-04-09 00:00:00 发表: 没有，显示的是awaiting reviewer scroes., objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=shaobom.shca, createdTime=Fri Apr 10 00:00:00 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581050, encodeId=a4a35810503e, content=您的是小修被拒吗？小太阳18 2019-12-04 00:00:00 发表: 同二审拒一审一个reviewer 一个editor 态度非常好没提补实验只需润色润色后二审一个月被拒 wtf , beContent=小太阳18 2019-12-04 00:00:00 发表: 同二审拒一审一个reviewer 一个editor 态度非常好没提补实验只需润色润色后二审一个月被拒 wtf , objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=435b2213876, createdName=120df541m40暂无昵称, createdTime=Fri Dec 06 00:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=)]

2021-10-05 浅沫

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤免疫治疗;病原生物
经验分享：再被cns子刊一顿拒稿之后，终于在这接收了。从投稿到接收，一直都非常迅速，感人主编很给力。
4.22提交 5.4一审大修遇到两个发nature大佬，提了一大堆意见，其中1号一直很很肯定我们的研究
6.23修回 7.14二审大修 2号审稿人同意接收，可惜1号换人了，提了几个和文章无关很无理的问题
9.15修回 9.24三审小修几个单词错误，迅速修回去
9.27修回 10.1 接收
希望大家都好运，搞个科研不容易

130 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1057918, encodeId=6cda105e9181e, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗;病原生物 经验分享：再被cns子刊一顿拒稿之后，终于在这接收了。从投稿到接收，一直都非常迅速，感人主编很给力。 4.22提交 5.4一审大修遇到两个发nature大佬，提了一大堆意见，其中1号一直很很肯定我们的研究 6.23修回 7.14二审大修 2号审稿人同意接收，可惜1号换人了，提了几个和文章无关很无理的问题 9.15修回 9.24三审小修几个单词错误，迅速修回去 9.27修回 10.1 接收 希望大家都好运，搞个科研不容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/07/ccdcbbe305c3370f7fc7637823aaeac0.jpg, createdBy=07fb2397125, createdName=浅沫, createdTime=Tue Oct 05 16:42:40 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099313, encodeId=d13520993130c, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：期刊效率非常高，对国人也比较友好 16-Aug-2022 Submitted 06-Sep-2022 Major Revision，大概1个月修回 24-Oct-2022 Minor Revision 03-Nov-2022 Accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epnJfSTyULHTUrbH2uCHYKgYccbS9AxlFkJ7ic0F0ZicWcM0LTv0LQibTtibeAeJRgWlLfdPBbicmPicPlw/132, createdBy=bd1f2020528, createdName=明日之星, createdTime=Wed Nov 09 08:12:06 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113407, encodeId=34b3211340e44, content=为什么这个杂志，一直是中科院二区？我有点想不通，小c d d，C a n c e r l e t t e r s这种都是一区了，是不是大水刊啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a452506975, createdName=124af5c7m81暂无昵称, createdTime=Tue Feb 07 11:15:57 CST 2023, time=2023-02-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1238075, encodeId=e32a12380e5ce, content=偏重的研究方向：肿瘤;生信 经验分享：请问这个杂志还收纯生信么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f79f6545001, createdName=ms8000001825855908, createdTime=Thu Aug 11 15:24:36 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231526, encodeId=d37d123152662, content=请问这个杂志接收case report么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211004/299253452aeb48dc9e0f8987e1a1cfe3/53348402bc724865bd8321a5f9b46bdb.jpg, createdBy=01db5551318, createdName=mkggdjkngfyikfddh, createdTime=Sat Jul 09 20:30:40 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107102, encodeId=c959110e102ff, content=文章题目需要注意些什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107101, encodeId=fbeb110e10100, content=文章题目应该包含哪些点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966060, encodeId=70539660602e, content=审稿速度:3.0 偏重的研究方向：肿瘤代谢;免疫 经验分享：中了一篇，审稿三月，修回后2个半月接收。感觉这个杂志目前的文章质量不错，基本都是老外的文章，期待杂志越办越好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0fa046123, createdName=mmz666, createdTime=Sun May 16 17:13:30 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588565, encodeId=6621588565d9, content=好的，谢谢vapor93 2020-04-09 00:00:00 发表: 没有，显示的是awaiting reviewer scroes., beContent=vapor93 2020-04-09 00:00:00 发表: 没有，显示的是awaiting reviewer scroes., objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=shaobom.shca, createdTime=Fri Apr 10 00:00:00 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581050, encodeId=a4a35810503e, content=您的是小修被拒吗？小太阳18 2019-12-04 00:00:00 发表: 同二审拒一审一个reviewer 一个editor 态度非常好没提补实验只需润色润色后二审一个月被拒 wtf , beContent=小太阳18 2019-12-04 00:00:00 发表: 同二审拒一审一个reviewer 一个editor 态度非常好没提补实验只需润色润色后二审一个月被拒 wtf , objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=435b2213876, createdName=120df541m40暂无昵称, createdTime=Fri Dec 06 00:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=)]

2022-11-09 明日之星

审稿速度:2.0 | 投稿命中率:50.0
经验分享：期刊效率非常高，对国人也比较友好
16-Aug-2022 Submitted
06-Sep-2022 Major Revision，大概1个月修回
24-Oct-2022 Minor Revision
03-Nov-2022 Accept

94 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1057918, encodeId=6cda105e9181e, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗;病原生物 经验分享：再被cns子刊一顿拒稿之后，终于在这接收了。从投稿到接收，一直都非常迅速，感人主编很给力。 4.22提交 5.4一审大修遇到两个发nature大佬，提了一大堆意见，其中1号一直很很肯定我们的研究 6.23修回 7.14二审大修 2号审稿人同意接收，可惜1号换人了，提了几个和文章无关很无理的问题 9.15修回 9.24三审小修几个单词错误，迅速修回去 9.27修回 10.1 接收 希望大家都好运，搞个科研不容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/07/ccdcbbe305c3370f7fc7637823aaeac0.jpg, createdBy=07fb2397125, createdName=浅沫, createdTime=Tue Oct 05 16:42:40 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099313, encodeId=d13520993130c, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：期刊效率非常高，对国人也比较友好 16-Aug-2022 Submitted 06-Sep-2022 Major Revision，大概1个月修回 24-Oct-2022 Minor Revision 03-Nov-2022 Accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epnJfSTyULHTUrbH2uCHYKgYccbS9AxlFkJ7ic0F0ZicWcM0LTv0LQibTtibeAeJRgWlLfdPBbicmPicPlw/132, createdBy=bd1f2020528, createdName=明日之星, createdTime=Wed Nov 09 08:12:06 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113407, encodeId=34b3211340e44, content=为什么这个杂志，一直是中科院二区？我有点想不通，小c d d，C a n c e r l e t t e r s这种都是一区了，是不是大水刊啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a452506975, createdName=124af5c7m81暂无昵称, createdTime=Tue Feb 07 11:15:57 CST 2023, time=2023-02-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1238075, encodeId=e32a12380e5ce, content=偏重的研究方向：肿瘤;生信 经验分享：请问这个杂志还收纯生信么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f79f6545001, createdName=ms8000001825855908, createdTime=Thu Aug 11 15:24:36 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231526, encodeId=d37d123152662, content=请问这个杂志接收case report么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211004/299253452aeb48dc9e0f8987e1a1cfe3/53348402bc724865bd8321a5f9b46bdb.jpg, createdBy=01db5551318, createdName=mkggdjkngfyikfddh, createdTime=Sat Jul 09 20:30:40 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107102, encodeId=c959110e102ff, content=文章题目需要注意些什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107101, encodeId=fbeb110e10100, content=文章题目应该包含哪些点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966060, encodeId=70539660602e, content=审稿速度:3.0 偏重的研究方向：肿瘤代谢;免疫 经验分享：中了一篇，审稿三月，修回后2个半月接收。感觉这个杂志目前的文章质量不错，基本都是老外的文章，期待杂志越办越好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0fa046123, createdName=mmz666, createdTime=Sun May 16 17:13:30 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588565, encodeId=6621588565d9, content=好的，谢谢vapor93 2020-04-09 00:00:00 发表: 没有，显示的是awaiting reviewer scroes., beContent=vapor93 2020-04-09 00:00:00 发表: 没有，显示的是awaiting reviewer scroes., objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=shaobom.shca, createdTime=Fri Apr 10 00:00:00 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581050, encodeId=a4a35810503e, content=您的是小修被拒吗？小太阳18 2019-12-04 00:00:00 发表: 同二审拒一审一个reviewer 一个editor 态度非常好没提补实验只需润色润色后二审一个月被拒 wtf , beContent=小太阳18 2019-12-04 00:00:00 发表: 同二审拒一审一个reviewer 一个editor 态度非常好没提补实验只需润色润色后二审一个月被拒 wtf , objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=435b2213876, createdName=120df541m40暂无昵称, createdTime=Fri Dec 06 00:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=)]

2023-02-07 124af5c7m81暂无昵称来自江苏省

为什么这个杂志，一直是中科院二区？我有点想不通，小c d d，C a n c e r l e t t e r s这种都是一区了，是不是大水刊啊？

24 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1057918, encodeId=6cda105e9181e, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗;病原生物 经验分享：再被cns子刊一顿拒稿之后，终于在这接收了。从投稿到接收，一直都非常迅速，感人主编很给力。 4.22提交 5.4一审大修遇到两个发nature大佬，提了一大堆意见，其中1号一直很很肯定我们的研究 6.23修回 7.14二审大修 2号审稿人同意接收，可惜1号换人了，提了几个和文章无关很无理的问题 9.15修回 9.24三审小修几个单词错误，迅速修回去 9.27修回 10.1 接收 希望大家都好运，搞个科研不容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/07/ccdcbbe305c3370f7fc7637823aaeac0.jpg, createdBy=07fb2397125, createdName=浅沫, createdTime=Tue Oct 05 16:42:40 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099313, encodeId=d13520993130c, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：期刊效率非常高，对国人也比较友好 16-Aug-2022 Submitted 06-Sep-2022 Major Revision，大概1个月修回 24-Oct-2022 Minor Revision 03-Nov-2022 Accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epnJfSTyULHTUrbH2uCHYKgYccbS9AxlFkJ7ic0F0ZicWcM0LTv0LQibTtibeAeJRgWlLfdPBbicmPicPlw/132, createdBy=bd1f2020528, createdName=明日之星, createdTime=Wed Nov 09 08:12:06 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113407, encodeId=34b3211340e44, content=为什么这个杂志，一直是中科院二区？我有点想不通，小c d d，C a n c e r l e t t e r s这种都是一区了，是不是大水刊啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a452506975, createdName=124af5c7m81暂无昵称, createdTime=Tue Feb 07 11:15:57 CST 2023, time=2023-02-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1238075, encodeId=e32a12380e5ce, content=偏重的研究方向：肿瘤;生信 经验分享：请问这个杂志还收纯生信么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f79f6545001, createdName=ms8000001825855908, createdTime=Thu Aug 11 15:24:36 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231526, encodeId=d37d123152662, content=请问这个杂志接收case report么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211004/299253452aeb48dc9e0f8987e1a1cfe3/53348402bc724865bd8321a5f9b46bdb.jpg, createdBy=01db5551318, createdName=mkggdjkngfyikfddh, createdTime=Sat Jul 09 20:30:40 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107102, encodeId=c959110e102ff, content=文章题目需要注意些什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107101, encodeId=fbeb110e10100, content=文章题目应该包含哪些点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966060, encodeId=70539660602e, content=审稿速度:3.0 偏重的研究方向：肿瘤代谢;免疫 经验分享：中了一篇，审稿三月，修回后2个半月接收。感觉这个杂志目前的文章质量不错，基本都是老外的文章，期待杂志越办越好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0fa046123, createdName=mmz666, createdTime=Sun May 16 17:13:30 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588565, encodeId=6621588565d9, content=好的，谢谢vapor93 2020-04-09 00:00:00 发表: 没有，显示的是awaiting reviewer scroes., beContent=vapor93 2020-04-09 00:00:00 发表: 没有，显示的是awaiting reviewer scroes., objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=shaobom.shca, createdTime=Fri Apr 10 00:00:00 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581050, encodeId=a4a35810503e, content=您的是小修被拒吗？小太阳18 2019-12-04 00:00:00 发表: 同二审拒一审一个reviewer 一个editor 态度非常好没提补实验只需润色润色后二审一个月被拒 wtf , beContent=小太阳18 2019-12-04 00:00:00 发表: 同二审拒一审一个reviewer 一个editor 态度非常好没提补实验只需润色润色后二审一个月被拒 wtf , objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=435b2213876, createdName=120df541m40暂无昵称, createdTime=Fri Dec 06 00:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=)]

2022-08-11 ms8000001825855908

偏重的研究方向：肿瘤;生信
经验分享：请问这个杂志还收纯生信么

58 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1057918, encodeId=6cda105e9181e, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗;病原生物 经验分享：再被cns子刊一顿拒稿之后，终于在这接收了。从投稿到接收，一直都非常迅速，感人主编很给力。 4.22提交 5.4一审大修遇到两个发nature大佬，提了一大堆意见，其中1号一直很很肯定我们的研究 6.23修回 7.14二审大修 2号审稿人同意接收，可惜1号换人了，提了几个和文章无关很无理的问题 9.15修回 9.24三审小修几个单词错误，迅速修回去 9.27修回 10.1 接收 希望大家都好运，搞个科研不容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/07/ccdcbbe305c3370f7fc7637823aaeac0.jpg, createdBy=07fb2397125, createdName=浅沫, createdTime=Tue Oct 05 16:42:40 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099313, encodeId=d13520993130c, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：期刊效率非常高，对国人也比较友好 16-Aug-2022 Submitted 06-Sep-2022 Major Revision，大概1个月修回 24-Oct-2022 Minor Revision 03-Nov-2022 Accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epnJfSTyULHTUrbH2uCHYKgYccbS9AxlFkJ7ic0F0ZicWcM0LTv0LQibTtibeAeJRgWlLfdPBbicmPicPlw/132, createdBy=bd1f2020528, createdName=明日之星, createdTime=Wed Nov 09 08:12:06 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113407, encodeId=34b3211340e44, content=为什么这个杂志，一直是中科院二区？我有点想不通，小c d d，C a n c e r l e t t e r s这种都是一区了，是不是大水刊啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a452506975, createdName=124af5c7m81暂无昵称, createdTime=Tue Feb 07 11:15:57 CST 2023, time=2023-02-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1238075, encodeId=e32a12380e5ce, content=偏重的研究方向：肿瘤;生信 经验分享：请问这个杂志还收纯生信么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f79f6545001, createdName=ms8000001825855908, createdTime=Thu Aug 11 15:24:36 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231526, encodeId=d37d123152662, content=请问这个杂志接收case report么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211004/299253452aeb48dc9e0f8987e1a1cfe3/53348402bc724865bd8321a5f9b46bdb.jpg, createdBy=01db5551318, createdName=mkggdjkngfyikfddh, createdTime=Sat Jul 09 20:30:40 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107102, encodeId=c959110e102ff, content=文章题目需要注意些什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107101, encodeId=fbeb110e10100, content=文章题目应该包含哪些点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966060, encodeId=70539660602e, content=审稿速度:3.0 偏重的研究方向：肿瘤代谢;免疫 经验分享：中了一篇，审稿三月，修回后2个半月接收。感觉这个杂志目前的文章质量不错，基本都是老外的文章，期待杂志越办越好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0fa046123, createdName=mmz666, createdTime=Sun May 16 17:13:30 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588565, encodeId=6621588565d9, content=好的，谢谢vapor93 2020-04-09 00:00:00 发表: 没有，显示的是awaiting reviewer scroes., beContent=vapor93 2020-04-09 00:00:00 发表: 没有，显示的是awaiting reviewer scroes., objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=shaobom.shca, createdTime=Fri Apr 10 00:00:00 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581050, encodeId=a4a35810503e, content=您的是小修被拒吗？小太阳18 2019-12-04 00:00:00 发表: 同二审拒一审一个reviewer 一个editor 态度非常好没提补实验只需润色润色后二审一个月被拒 wtf , beContent=小太阳18 2019-12-04 00:00:00 发表: 同二审拒一审一个reviewer 一个editor 态度非常好没提补实验只需润色润色后二审一个月被拒 wtf , objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=435b2213876, createdName=120df541m40暂无昵称, createdTime=Fri Dec 06 00:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=)]

2022-07-09 mkggdjkngfyikfddh

请问这个杂志接收case report么

48 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1057918, encodeId=6cda105e9181e, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗;病原生物 经验分享：再被cns子刊一顿拒稿之后，终于在这接收了。从投稿到接收，一直都非常迅速，感人主编很给力。 4.22提交 5.4一审大修遇到两个发nature大佬，提了一大堆意见，其中1号一直很很肯定我们的研究 6.23修回 7.14二审大修 2号审稿人同意接收，可惜1号换人了，提了几个和文章无关很无理的问题 9.15修回 9.24三审小修几个单词错误，迅速修回去 9.27修回 10.1 接收 希望大家都好运，搞个科研不容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/07/ccdcbbe305c3370f7fc7637823aaeac0.jpg, createdBy=07fb2397125, createdName=浅沫, createdTime=Tue Oct 05 16:42:40 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099313, encodeId=d13520993130c, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：期刊效率非常高，对国人也比较友好 16-Aug-2022 Submitted 06-Sep-2022 Major Revision，大概1个月修回 24-Oct-2022 Minor Revision 03-Nov-2022 Accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epnJfSTyULHTUrbH2uCHYKgYccbS9AxlFkJ7ic0F0ZicWcM0LTv0LQibTtibeAeJRgWlLfdPBbicmPicPlw/132, createdBy=bd1f2020528, createdName=明日之星, createdTime=Wed Nov 09 08:12:06 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113407, encodeId=34b3211340e44, content=为什么这个杂志，一直是中科院二区？我有点想不通，小c d d，C a n c e r l e t t e r s这种都是一区了，是不是大水刊啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a452506975, createdName=124af5c7m81暂无昵称, createdTime=Tue Feb 07 11:15:57 CST 2023, time=2023-02-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1238075, encodeId=e32a12380e5ce, content=偏重的研究方向：肿瘤;生信 经验分享：请问这个杂志还收纯生信么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f79f6545001, createdName=ms8000001825855908, createdTime=Thu Aug 11 15:24:36 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231526, encodeId=d37d123152662, content=请问这个杂志接收case report么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211004/299253452aeb48dc9e0f8987e1a1cfe3/53348402bc724865bd8321a5f9b46bdb.jpg, createdBy=01db5551318, createdName=mkggdjkngfyikfddh, createdTime=Sat Jul 09 20:30:40 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107102, encodeId=c959110e102ff, content=文章题目需要注意些什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107101, encodeId=fbeb110e10100, content=文章题目应该包含哪些点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966060, encodeId=70539660602e, content=审稿速度:3.0 偏重的研究方向：肿瘤代谢;免疫 经验分享：中了一篇，审稿三月，修回后2个半月接收。感觉这个杂志目前的文章质量不错，基本都是老外的文章，期待杂志越办越好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0fa046123, createdName=mmz666, createdTime=Sun May 16 17:13:30 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588565, encodeId=6621588565d9, content=好的，谢谢vapor93 2020-04-09 00:00:00 发表: 没有，显示的是awaiting reviewer scroes., beContent=vapor93 2020-04-09 00:00:00 发表: 没有，显示的是awaiting reviewer scroes., objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=shaobom.shca, createdTime=Fri Apr 10 00:00:00 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581050, encodeId=a4a35810503e, content=您的是小修被拒吗？小太阳18 2019-12-04 00:00:00 发表: 同二审拒一审一个reviewer 一个editor 态度非常好没提补实验只需润色润色后二审一个月被拒 wtf , beContent=小太阳18 2019-12-04 00:00:00 发表: 同二审拒一审一个reviewer 一个editor 态度非常好没提补实验只需润色润色后二审一个月被拒 wtf , objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=435b2213876, createdName=120df541m40暂无昵称, createdTime=Fri Dec 06 00:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=)]

2021-12-29 ms6000000264964247

文章题目需要注意些什么？

54 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1057918, encodeId=6cda105e9181e, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗;病原生物 经验分享：再被cns子刊一顿拒稿之后，终于在这接收了。从投稿到接收，一直都非常迅速，感人主编很给力。 4.22提交 5.4一审大修遇到两个发nature大佬，提了一大堆意见，其中1号一直很很肯定我们的研究 6.23修回 7.14二审大修 2号审稿人同意接收，可惜1号换人了，提了几个和文章无关很无理的问题 9.15修回 9.24三审小修几个单词错误，迅速修回去 9.27修回 10.1 接收 希望大家都好运，搞个科研不容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/07/ccdcbbe305c3370f7fc7637823aaeac0.jpg, createdBy=07fb2397125, createdName=浅沫, createdTime=Tue Oct 05 16:42:40 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099313, encodeId=d13520993130c, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：期刊效率非常高，对国人也比较友好 16-Aug-2022 Submitted 06-Sep-2022 Major Revision，大概1个月修回 24-Oct-2022 Minor Revision 03-Nov-2022 Accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epnJfSTyULHTUrbH2uCHYKgYccbS9AxlFkJ7ic0F0ZicWcM0LTv0LQibTtibeAeJRgWlLfdPBbicmPicPlw/132, createdBy=bd1f2020528, createdName=明日之星, createdTime=Wed Nov 09 08:12:06 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113407, encodeId=34b3211340e44, content=为什么这个杂志，一直是中科院二区？我有点想不通，小c d d，C a n c e r l e t t e r s这种都是一区了，是不是大水刊啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a452506975, createdName=124af5c7m81暂无昵称, createdTime=Tue Feb 07 11:15:57 CST 2023, time=2023-02-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1238075, encodeId=e32a12380e5ce, content=偏重的研究方向：肿瘤;生信 经验分享：请问这个杂志还收纯生信么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f79f6545001, createdName=ms8000001825855908, createdTime=Thu Aug 11 15:24:36 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231526, encodeId=d37d123152662, content=请问这个杂志接收case report么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211004/299253452aeb48dc9e0f8987e1a1cfe3/53348402bc724865bd8321a5f9b46bdb.jpg, createdBy=01db5551318, createdName=mkggdjkngfyikfddh, createdTime=Sat Jul 09 20:30:40 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107102, encodeId=c959110e102ff, content=文章题目需要注意些什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107101, encodeId=fbeb110e10100, content=文章题目应该包含哪些点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966060, encodeId=70539660602e, content=审稿速度:3.0 偏重的研究方向：肿瘤代谢;免疫 经验分享：中了一篇，审稿三月，修回后2个半月接收。感觉这个杂志目前的文章质量不错，基本都是老外的文章，期待杂志越办越好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0fa046123, createdName=mmz666, createdTime=Sun May 16 17:13:30 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588565, encodeId=6621588565d9, content=好的，谢谢vapor93 2020-04-09 00:00:00 发表: 没有，显示的是awaiting reviewer scroes., beContent=vapor93 2020-04-09 00:00:00 发表: 没有，显示的是awaiting reviewer scroes., objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=shaobom.shca, createdTime=Fri Apr 10 00:00:00 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581050, encodeId=a4a35810503e, content=您的是小修被拒吗？小太阳18 2019-12-04 00:00:00 发表: 同二审拒一审一个reviewer 一个editor 态度非常好没提补实验只需润色润色后二审一个月被拒 wtf , beContent=小太阳18 2019-12-04 00:00:00 发表: 同二审拒一审一个reviewer 一个editor 态度非常好没提补实验只需润色润色后二审一个月被拒 wtf , objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=435b2213876, createdName=120df541m40暂无昵称, createdTime=Fri Dec 06 00:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=)]

2021-12-29 乌云背后的幸福线

文章题目应该包含哪些点？

48 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1057918, encodeId=6cda105e9181e, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗;病原生物 经验分享：再被cns子刊一顿拒稿之后，终于在这接收了。从投稿到接收，一直都非常迅速，感人主编很给力。 4.22提交 5.4一审大修遇到两个发nature大佬，提了一大堆意见，其中1号一直很很肯定我们的研究 6.23修回 7.14二审大修 2号审稿人同意接收，可惜1号换人了，提了几个和文章无关很无理的问题 9.15修回 9.24三审小修几个单词错误，迅速修回去 9.27修回 10.1 接收 希望大家都好运，搞个科研不容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/07/ccdcbbe305c3370f7fc7637823aaeac0.jpg, createdBy=07fb2397125, createdName=浅沫, createdTime=Tue Oct 05 16:42:40 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099313, encodeId=d13520993130c, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：期刊效率非常高，对国人也比较友好 16-Aug-2022 Submitted 06-Sep-2022 Major Revision，大概1个月修回 24-Oct-2022 Minor Revision 03-Nov-2022 Accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epnJfSTyULHTUrbH2uCHYKgYccbS9AxlFkJ7ic0F0ZicWcM0LTv0LQibTtibeAeJRgWlLfdPBbicmPicPlw/132, createdBy=bd1f2020528, createdName=明日之星, createdTime=Wed Nov 09 08:12:06 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113407, encodeId=34b3211340e44, content=为什么这个杂志，一直是中科院二区？我有点想不通，小c d d，C a n c e r l e t t e r s这种都是一区了，是不是大水刊啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a452506975, createdName=124af5c7m81暂无昵称, createdTime=Tue Feb 07 11:15:57 CST 2023, time=2023-02-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1238075, encodeId=e32a12380e5ce, content=偏重的研究方向：肿瘤;生信 经验分享：请问这个杂志还收纯生信么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f79f6545001, createdName=ms8000001825855908, createdTime=Thu Aug 11 15:24:36 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231526, encodeId=d37d123152662, content=请问这个杂志接收case report么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211004/299253452aeb48dc9e0f8987e1a1cfe3/53348402bc724865bd8321a5f9b46bdb.jpg, createdBy=01db5551318, createdName=mkggdjkngfyikfddh, createdTime=Sat Jul 09 20:30:40 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107102, encodeId=c959110e102ff, content=文章题目需要注意些什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107101, encodeId=fbeb110e10100, content=文章题目应该包含哪些点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966060, encodeId=70539660602e, content=审稿速度:3.0 偏重的研究方向：肿瘤代谢;免疫 经验分享：中了一篇，审稿三月，修回后2个半月接收。感觉这个杂志目前的文章质量不错，基本都是老外的文章，期待杂志越办越好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0fa046123, createdName=mmz666, createdTime=Sun May 16 17:13:30 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588565, encodeId=6621588565d9, content=好的，谢谢vapor93 2020-04-09 00:00:00 发表: 没有，显示的是awaiting reviewer scroes., beContent=vapor93 2020-04-09 00:00:00 发表: 没有，显示的是awaiting reviewer scroes., objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=shaobom.shca, createdTime=Fri Apr 10 00:00:00 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581050, encodeId=a4a35810503e, content=您的是小修被拒吗？小太阳18 2019-12-04 00:00:00 发表: 同二审拒一审一个reviewer 一个editor 态度非常好没提补实验只需润色润色后二审一个月被拒 wtf , beContent=小太阳18 2019-12-04 00:00:00 发表: 同二审拒一审一个reviewer 一个editor 态度非常好没提补实验只需润色润色后二审一个月被拒 wtf , objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=435b2213876, createdName=120df541m40暂无昵称, createdTime=Fri Dec 06 00:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=)]

2021-05-16 mmz666

审稿速度:3.0
偏重的研究方向：肿瘤代谢;免疫
经验分享：中了一篇，审稿三月，修回后2个半月接收。感觉这个杂志目前的文章质量不错，基本都是老外的文章，期待杂志越办越好

158 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1057918, encodeId=6cda105e9181e, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗;病原生物 经验分享：再被cns子刊一顿拒稿之后，终于在这接收了。从投稿到接收，一直都非常迅速，感人主编很给力。 4.22提交 5.4一审大修遇到两个发nature大佬，提了一大堆意见，其中1号一直很很肯定我们的研究 6.23修回 7.14二审大修 2号审稿人同意接收，可惜1号换人了，提了几个和文章无关很无理的问题 9.15修回 9.24三审小修几个单词错误，迅速修回去 9.27修回 10.1 接收 希望大家都好运，搞个科研不容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/07/ccdcbbe305c3370f7fc7637823aaeac0.jpg, createdBy=07fb2397125, createdName=浅沫, createdTime=Tue Oct 05 16:42:40 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099313, encodeId=d13520993130c, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：期刊效率非常高，对国人也比较友好 16-Aug-2022 Submitted 06-Sep-2022 Major Revision，大概1个月修回 24-Oct-2022 Minor Revision 03-Nov-2022 Accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epnJfSTyULHTUrbH2uCHYKgYccbS9AxlFkJ7ic0F0ZicWcM0LTv0LQibTtibeAeJRgWlLfdPBbicmPicPlw/132, createdBy=bd1f2020528, createdName=明日之星, createdTime=Wed Nov 09 08:12:06 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113407, encodeId=34b3211340e44, content=为什么这个杂志，一直是中科院二区？我有点想不通，小c d d，C a n c e r l e t t e r s这种都是一区了，是不是大水刊啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a452506975, createdName=124af5c7m81暂无昵称, createdTime=Tue Feb 07 11:15:57 CST 2023, time=2023-02-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1238075, encodeId=e32a12380e5ce, content=偏重的研究方向：肿瘤;生信 经验分享：请问这个杂志还收纯生信么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f79f6545001, createdName=ms8000001825855908, createdTime=Thu Aug 11 15:24:36 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231526, encodeId=d37d123152662, content=请问这个杂志接收case report么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211004/299253452aeb48dc9e0f8987e1a1cfe3/53348402bc724865bd8321a5f9b46bdb.jpg, createdBy=01db5551318, createdName=mkggdjkngfyikfddh, createdTime=Sat Jul 09 20:30:40 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107102, encodeId=c959110e102ff, content=文章题目需要注意些什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107101, encodeId=fbeb110e10100, content=文章题目应该包含哪些点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966060, encodeId=70539660602e, content=审稿速度:3.0 偏重的研究方向：肿瘤代谢;免疫 经验分享：中了一篇，审稿三月，修回后2个半月接收。感觉这个杂志目前的文章质量不错，基本都是老外的文章，期待杂志越办越好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0fa046123, createdName=mmz666, createdTime=Sun May 16 17:13:30 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588565, encodeId=6621588565d9, content=好的，谢谢vapor93 2020-04-09 00:00:00 发表: 没有，显示的是awaiting reviewer scroes., beContent=vapor93 2020-04-09 00:00:00 发表: 没有，显示的是awaiting reviewer scroes., objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=shaobom.shca, createdTime=Fri Apr 10 00:00:00 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581050, encodeId=a4a35810503e, content=您的是小修被拒吗？小太阳18 2019-12-04 00:00:00 发表: 同二审拒一审一个reviewer 一个editor 态度非常好没提补实验只需润色润色后二审一个月被拒 wtf , beContent=小太阳18 2019-12-04 00:00:00 发表: 同二审拒一审一个reviewer 一个editor 态度非常好没提补实验只需润色润色后二审一个月被拒 wtf , objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=435b2213876, createdName=120df541m40暂无昵称, createdTime=Fri Dec 06 00:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=)]

2020-04-10 shaobom.shca

好的，谢谢vapor93 2020-04-09 00:00:00 发表:
没有，显示的是awaiting reviewer scroes.

vapor93 2020-04-09 00:00:00 发表: 没有，显示的是awaiting reviewer scroes.

131 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1057918, encodeId=6cda105e9181e, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗;病原生物 经验分享：再被cns子刊一顿拒稿之后，终于在这接收了。从投稿到接收，一直都非常迅速，感人主编很给力。 4.22提交 5.4一审大修遇到两个发nature大佬，提了一大堆意见，其中1号一直很很肯定我们的研究 6.23修回 7.14二审大修 2号审稿人同意接收，可惜1号换人了，提了几个和文章无关很无理的问题 9.15修回 9.24三审小修几个单词错误，迅速修回去 9.27修回 10.1 接收 希望大家都好运，搞个科研不容易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/07/ccdcbbe305c3370f7fc7637823aaeac0.jpg, createdBy=07fb2397125, createdName=浅沫, createdTime=Tue Oct 05 16:42:40 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099313, encodeId=d13520993130c, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：期刊效率非常高，对国人也比较友好 16-Aug-2022 Submitted 06-Sep-2022 Major Revision，大概1个月修回 24-Oct-2022 Minor Revision 03-Nov-2022 Accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epnJfSTyULHTUrbH2uCHYKgYccbS9AxlFkJ7ic0F0ZicWcM0LTv0LQibTtibeAeJRgWlLfdPBbicmPicPlw/132, createdBy=bd1f2020528, createdName=明日之星, createdTime=Wed Nov 09 08:12:06 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113407, encodeId=34b3211340e44, content=为什么这个杂志，一直是中科院二区？我有点想不通，小c d d，C a n c e r l e t t e r s这种都是一区了，是不是大水刊啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a452506975, createdName=124af5c7m81暂无昵称, createdTime=Tue Feb 07 11:15:57 CST 2023, time=2023-02-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1238075, encodeId=e32a12380e5ce, content=偏重的研究方向：肿瘤;生信 经验分享：请问这个杂志还收纯生信么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f79f6545001, createdName=ms8000001825855908, createdTime=Thu Aug 11 15:24:36 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231526, encodeId=d37d123152662, content=请问这个杂志接收case report么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211004/299253452aeb48dc9e0f8987e1a1cfe3/53348402bc724865bd8321a5f9b46bdb.jpg, createdBy=01db5551318, createdName=mkggdjkngfyikfddh, createdTime=Sat Jul 09 20:30:40 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107102, encodeId=c959110e102ff, content=文章题目需要注意些什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107101, encodeId=fbeb110e10100, content=文章题目应该包含哪些点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966060, encodeId=70539660602e, content=审稿速度:3.0 偏重的研究方向：肿瘤代谢;免疫 经验分享：中了一篇，审稿三月，修回后2个半月接收。感觉这个杂志目前的文章质量不错，基本都是老外的文章，期待杂志越办越好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0fa046123, createdName=mmz666, createdTime=Sun May 16 17:13:30 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588565, encodeId=6621588565d9, content=好的，谢谢vapor93 2020-04-09 00:00:00 发表: 没有，显示的是awaiting reviewer scroes., beContent=vapor93 2020-04-09 00:00:00 发表: 没有，显示的是awaiting reviewer scroes., objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=shaobom.shca, createdTime=Fri Apr 10 00:00:00 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=581050, encodeId=a4a35810503e, content=您的是小修被拒吗？小太阳18 2019-12-04 00:00:00 发表: 同二审拒一审一个reviewer 一个editor 态度非常好没提补实验只需润色润色后二审一个月被拒 wtf , beContent=小太阳18 2019-12-04 00:00:00 发表: 同二审拒一审一个reviewer 一个editor 态度非常好没提补实验只需润色润色后二审一个月被拒 wtf , objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=435b2213876, createdName=120df541m40暂无昵称, createdTime=Fri Dec 06 00:00:00 CST 2019, time=2019-12-06, status=1, ipAttribution=)]

2019-12-06 120df541m40暂无昵称

您的是小修被拒吗？小太阳18 2019-12-04 00:00:00 发表:
同二审拒一审一个reviewer 一个editor 态度非常好没提补实验只需润色润色后二审一个月被拒 wtf

小太阳18 2019-12-04 00:00:00 发表: 同二审拒一审一个reviewer 一个editor 态度非常好没提补实验只需润色润色后二审一个月被拒 wtf

155 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务